Disclosed is a use of (a) a connexin agent and (b) an antagonist of VEGF effective in promoting or improving healing, in the manufacture of a medicament for promoting or improving healing of optic nerve or eye tissue in a subject in need thereof wherein the connexin agent is an anti-connexin 43 polynucleotide or a connexin peptide or peptidomimetic and wherein the medicament is formulated for separate, sequential or simultaneous administration of (a) and (b).
